Amgen Inc
NASDAQ:AMGN

Watchlist Manager
Amgen Inc Logo
Amgen Inc
NASDAQ:AMGN
Watchlist
Price: 263.38 USD 0.84% Market Closed
Market Cap: 141.6B USD
Have any thoughts about
Amgen Inc?
Write Note

Amgen Inc
Cash from Investing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Amgen Inc
Cash from Investing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Investing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Amgen Inc
NASDAQ:AMGN
Cash from Investing Activities
-$27.7B
CAGR 3-Years
-304%
CAGR 5-Years
N/A
CAGR 10-Years
-5%
Abbvie Inc
NYSE:ABBV
Cash from Investing Activities
-$19.7B
CAGR 3-Years
-121%
CAGR 5-Years
N/A
CAGR 10-Years
-20%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Investing Activities
-$4B
CAGR 3-Years
31%
CAGR 5-Years
6%
CAGR 10-Years
-13%
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Cash from Investing Activities
-$304.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Investing Activities
-$3.8B
CAGR 3-Years
N/A
CAGR 5-Years
-59%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Investing Activities
-$2.9B
CAGR 3-Years
8%
CAGR 5-Years
-7%
CAGR 10-Years
-17%
No Stocks Found

Amgen Inc
Glance View

Market Cap
141.6B USD
Industry
Biotechnology
Economic Moat
Wide

Amgen Inc., a towering figure in the biopharmaceutical industry, started its journey in the early 1980s in Thousand Oaks, California, with a visionary commitment to tapping into the potential of recombinant DNA technology. This leap into biotechnology allowed the company to produce vital proteins that the body naturally lacks in certain medical conditions. Concentrating on serious illnesses such as cancer, kidney failure, and rheumatoid arthritis, Amgen transformed itself over the decades from a novel research lab into a global powerhouse, rolling out revolutionary therapies like Epogen and Neulasta. These blockbuster drugs, designed to treat anemia and prevent infections in chemotherapy patients, catapulted Amgen into the echelon of companies that not only evolve with science but also shape its trajectory. Today, Amgen thrives by blending its innovative science with strategic acquisitions, expanding its pipeline beyond merely biological drugs to include biosimilars and small molecule medicines. The company's revenue stream relies heavily on its existing successful therapies while also banking on the future with investments in genetic research and novel drug developments. By leveraging their expertise in biotechnology and clinical trials, Amgen is able to bring new products to market and navigate the complex regulatory landscape efficiently. The firm expertly balances risk and reward, ensuring a steady influx of cash flow through both established product lines and the advent of new therapies. Thus, Amgen, with its robust portfolio and strategic business maneuvers, continues to play a pivotal role in enhancing patient outcomes while reinforcing its position as a leader in the biopharmaceutical realm.

AMGN Intrinsic Value
247.23 USD
Overvaluation 6%
Intrinsic Value
Price

See Also

What is Amgen Inc's Cash from Investing Activities?
Cash from Investing Activities
-27.7B USD

Based on the financial report for Sep 30, 2024, Amgen Inc's Cash from Investing Activities amounts to -27.7B USD.

What is Amgen Inc's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 10Y
-5%

Over the last year, the Cash from Investing Activities growth was -972%. The average annual Cash from Investing Activities growth rates for Amgen Inc have been -304% over the past three years , and -5% over the past ten years .

Back to Top